Defense Secretary Pete Hegseth rolled out a new health screening initiative this week that will test testosterone levels in active-duty troops aged 30 and older, with the stated goal of keeping soldiers operating at peak physical performance. The program would offer opt-in testosterone replacement therapy to those found to have insufficient levels.
Hegseth announced the policy in a video posted to X, labeling it part of a "High-T Department of War" focused on maintaining combat readiness. "By addressing these health markers early, we're keeping you on the leading edge of lethality," the defense secretary said in the announcement.
The policy raises immediate questions about scope and intent. While the video doesn't explicitly address whether women would be included in the screening, reporting indicates the program would apply to female service members as well. Yet the absence of FDA-approved testosterone treatments for women suggests the therapy component would effectively target male troops only.
That distinction carries particular weight given Hegseth's documented resistance to expanding women's roles in the military. Though he reversed his categorical opposition to female combat troops during his confirmation process, his recent actions tell a different story. In a highly unusual move, Hegseth blocked the promotions of seven senior naval officers to two-star admiral rank, five of whom are women or people of color. The result, according to the New York Times, is that no female active-duty naval officers are likely to be promoted to admiral this year for the first time in more than a decade.
The testosterone initiative also raises eyebrows given the Trump administration's previous stance on medical spending for troops. The administration has pushed to bar transgender individuals from military service, citing the expense of gender-affirming care as a budgetary concern. Meanwhile, the Pentagon spends roughly ten times as much on erectile dysfunction medications like Viagra than on healthcare services for transgender service members, suggesting resource constraints are selectively applied.
The timing of the announcement compounds questions about departmental priorities. On the same day Hegseth unveiled the testosterone screening program, Iran threatened to halt all energy exports from the Middle East in response to U.S. sanctions, and President Trump warned of escalating military strikes against the country. The escalating tension underscores an ongoing conflict with no clear exit strategy and mounting costs already reaching tens of billions of dollars.
For a defense secretary juggling geopolitical crises, military strategy decisions, and diplomatic negotiations, a hormone-screening initiative appears to occupy considerable bandwidth and institutional focus at a moment when other urgent challenges demand attention.
Author James Rodriguez: "A defense secretary has bigger fish to fry than viral videos about testosterone levels, especially when actual war is heating up in the Middle East."
Comments